Pegylated liposomal doxorubicin in stage IVB mycosis fungoides

Giuseppe Di Lorenzo, R. Di Trolio, M. Delfino, S. De Placido

Research output: Contribution to journalArticlepeer-review


Background: Previous studies have shown that pegylated liposomal doxorubicin (LD) is effective in the treatment of relapsing or recalcitrant cutaneous T-cell lymphoma. Objectives: To evaluate the activity and toxicity of LD in patients with stage IVB mycosis fungoides (MF). Methods: In this retrospective study, we evaluated outcomes and recorded adverse effects in 10 patients with MF (seven men and three women) with extracutaneous involvement. Patients were treated with LD 20 mg m-2 administered intravenously every 4 weeks. Results: All patients received at least two cycles of LD, three patients received four cycles and one patient received six cycles. Three patients (30%) had a partial response and two patients had stable disease. Grade 1-2 leucopenia occurred in three of the 10 patients, and grade 4 leucopenia in one. Three patients had grade 2 palmoplantar erythrodysaesthesia. Conclusions: This study demonstrates that LD is beneficial in terms of activity and toxicity in stage IVB MF. These observations should be verified in larger studies.

Original languageEnglish
Pages (from-to)183-185
Number of pages3
JournalBritish Journal of Dermatology
Issue number1
Publication statusPublished - Jul 2005


  • Advanced disease
  • Chemotherapy
  • Mycosis fungoides
  • Pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Pegylated liposomal doxorubicin in stage IVB mycosis fungoides'. Together they form a unique fingerprint.

Cite this